Sign in with Google. Opens in new tab
Sun Pharmaceutical (SUNP IN): Checkpoint Acquisition Does Not Check All the Boxes
445 Views10 Mar 2025 09:47
SUMMARY
- Sun Pharmaceutical Industries (SUNP IN) (SPIL) announced the plan to acquire Checkpoint Therapeutics (CKPT US), a commercial stage immunotherapy and targeted oncology company, for ~$200M.
- In December, Checkpoint has received FDA approval for its maiden drug, Unloxcyt (cosibelimab), for the treatment of certain type of skin cancer. Unloxcyt has peak sales estimate of $1.6B.
- SPIL’s offer for Checkpoint seems compelling and provides superior risk-adjusted value. However, the acquisition will not be near-term value generator for SPIL, which doesn’t have good track record for acquisition.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- PointsBet (PBH AU): Betr's "Superior Offer"? In An Alternate Reality
- Xero (XRO AU): Index Flows Following the Capital Raise
- NIFTY200 Momentum30 Index Rebalance: HUGE Turnover and Trade as Financials Shine
- Shin Kong (2888 TT)/Taishin (2887 TT) - Short Timer, FX Risk, Index Flows - Time To Buy Vs Peers
- Laopu Gold (6181 HK): Lockup Expiry Ahead. After 2000% Rally, Is There Still Shine Left?
Top Unpaywalled Insights
More »- The New OS for Quant Finance: OpenBB, AI Agents & the Death of Legacy Terminals | New Barbarians ...
- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- [IO Technicals 2025/25] Bearish Momentum Strengthens
- VEON (VEON US): Launches Third Phase of Share Buyback Program After Share Pullback
- Valuations, Visas & Venture Pullback: An Equity + M&A Overview of the Education Sector in Q1 2025
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Sun Pharmaceutical (SUNP IN): Timely Succession Plan to Augur Well for Next-Level of Growth14 Jun 2025
- Sun Pharmaceutical (SUNP IN): Checkpoint Acquisition Does Not Check All the Boxes10 Mar 2025
x